Boosting beta-cell function for treatment of type 1 diabetes KU Leuven
In type 1 diabetic (T1D) patients the pancreatic insulin-producing beta cells are selective destroyed by the immune system, leading to an impaired glucose metabolism. The steep increase in the incidence of this chronic autoimmune pathology especially in young children in the last decades raises serious concerns. To date, insulin therapy is considered the gold standard for the treatment of T1D. Nevertheless, limitations persist, such as the ...